ISBN: 978-81-985724-3-1

NEXUS KNOWLEDGE PUBLICATION

https://nknpub.com/index.php/1

Precision Oncology: Innovations in Diagnosis, Drug Delivery, And Patient Care



Published By – Nexus Knowledge Publication

(Imprint of AKT Multitask Consultancy)

Bilaspur, Chhattisgarh, India, 495006

www.aktmultitask.com

Chapter- 9

PATIENT STRATIFICATION AND ADAPTIVE CLINICAL TRIALS

MONIKA KASHYAP
Assistant Professor
Institute of Pharmaceutical Sciences, IET Bhaddal
Pin - 140108
Email: mk32ei@gmail.com

Dr. B SABANA
Assistant Professor,
Department of Biochemistry and Bioinformatics,
Dr. MGR Janaki College for Women, Adyar

Mr. GADGE SHUBHAM CHANDRAKANT
Assistant Professor
Department of Pharmacology
Samarth Institute of Pharmacy, Belhe
On Nagar kalyan Highway At-Bangarwadi Post-Belhe, 412410
Email: shubhamgadge2208@gmail.com

Dr. P. SHOBANA
Assistant Professor
Sri Shanmugha college of Pharmacy, Sankari
Email: shobanaragavan949@gmail.com

Mr. JYOTIPRAKASH BHANJA
Assistant Professor
Department of Pharmacology
Akash Institute of Pharmaceutical Education and Technology
Mahipal, Kendrapara, Odisha, India. 754211
Email: jyotiprbhanja@gmail.com

DOI 10.5281/zenodo.17199086

ISBN: 978-81-985724-3-1

ISBN: 978-81-985724-3-1

Chapter 9…

PATIENT STRATIFICATION AND ADAPTIVE CLINICAL TRIALS

MONIKA KASHYAP
Assistant Professor
Institute of Pharmaceutical Sciences, IET Bhaddal
Pin - 140108
Email: mk32ei@gmail.com

Dr. B SABANA
Assistant Professor,
Department of Biochemistry and Bioinformatics,
Dr. MGR Janaki College for Women, Adyar

Mr. GADGE SHUBHAM CHANDRAKANT
Assistant Professor
Department of Pharmacology
Samarth Institute of Pharmacy, Belhe
On Nagar kalyan Highway At-Bangarwadi Post-Belhe, 412410
Email: shubhamgadge2208@gmail.com

Dr. P. SHOBANA
Assistant Professor
Sri Shanmugha college of Pharmacy, Sankari
Email: shobanaragavan949@gmail.com

Mr. JYOTIPRAKASH BHANJA
Assistant Professor
Department of Pharmacology
Akash Institute of Pharmaceutical Education and Technology
Mahipal, Kendrapara, Odisha, India. 754211
Email: jyotiprbhanja@gmail.com

ISBN: 978-81-985724-3-1

Conventional clinical trials in oncology often adhere to a fixed design, such that patients are randomized to pre-specified treatment arms, efficacy or safety are only evaluated at the study conclusion. Although this has been a classical method in the development of drugs, it has its significant shortcomings. Cancer is a disease that is heterogeneous in nature and even within the same histology there is a wide range of molecular, genomic, epigenetic and immunological characteristics of the tumors. Therefore, those treatments which are found to be effective in one subgroup might prove ineffective, or possibly harmful, in another, causing trial inefficiencies, long timeline, and exposing patients to ineffective therapies. The difficulties related to these challenges underscore the importance of more flexible and patient/tumor-specific trial designs capable of considering patient and tumor heterogeneity.



Figure 1: Patient Stratification Using Genetic and Genomic Biomarkers

Source: (https://www.researchgate.net/figure/Patient-stratification-using-genetic-and-genomic-biomarkers-Top-panel-shows-the_fig1_270289152)

Patient stratification is a solution to this problem by splitting patients into subgroups according to molecular or clinical attributes of predicting treatment response. Stratification based on biomarkers enables the researcher to determine groups of populations that are most likely to respond to certain interventions to increase the statistical strength and clinical utility of trials. To illustrate, treating patients containing a genetic mutation, e.g. EGFR mutations in lung cancer or BRCA mutations in breast and ovarian cancer, with targeted therapies enhances

ISBN: 978-81-985724-3-1

therapeutic effect and reduces non-response by unnecessary toxicity. Adding real-world evidence, such as data on electronic health records and registries, and past clinical trials, further streamlines stratification plans, offering information on variability in the response to treatment in larger groups of patients.

Adaptive clinical trial designs are used to complement stratification, and they permit dynamic changes in the study without affecting statistical rigor. Contrary to conventional fixed trials, adaptive trials are allowed to change things, e.g., sample size, treatment arms, or patient allocation, based on interim analyses. These real-time decisions are usually carried out using Bayesian and frequentism statistical models so that they can treat people ethically and make proper use of available resources. An example is that the expansion of promising treatment arms can be increased to recruit more patients, and ineffective arms can be minimized to reduced exposure to non-optimal treatment. Adaptive designs in oncology include seamless Phase II/III trials, umbrella trials that aim to test a single therapy across multiple molecular subtypes within a single tumor type as well as basket trials that test a single therapy in multiple cancers sharing the same mutation.

Combination of patient stratification and adaptive trial design is a paradigm shift in clinical oncology. These methods enhance the speed of clinical assessment of new therapies, maximize patient benefit, and personalized medicine by integrating molecular profiling, real-world data, and flexible trial structures. Also, they are more conducive to quicker regulatory decisions since adaptive trials are capable of producing strong evidence more effectively. All in all, the future of precision oncology and innovative trial methodology converging can allow revolutionizing the drug development of cancer not only in terms of efficiency of trials but also in terms of patient outcomes and reduced unnecessary exposure to ineffective treatment.

9.1. BASKET, UMBRELLA, AND PLATFORM TRIAL DESIGNS

Adaptive clinical trial designs have transformed the oncology research by matching therapies in patients based on their molecular and genetic features and the goal of optimizing their efficacy and efficiency. One of these methods includes basket trials, which have become an effective method to test one therapy in a variety of cancer types that have a common molecular change, like the BRAF V600E mutation. Rather than assessing the impact of therapy on the tissue of origin, basket trials assess the impact of therapy on mutation-driven processes, which allows drug development to be faster and studies rare mutations that otherwise would not have

ISBN: 978-81-985724-3-1

ample patients to examine. This design is especially beneficial in pooling patients with different tumor types, which will allow recruiting them faster and generating more evidence. Nevertheless, there are still obstacles, especially in dealing with the heterogeneity of tumor microenvironments across tissues and intricacies of carrying out powerful statistical analyses in small and heterogeneous subpopulations. Such constraints suggest the fragility of the trade-offs between innovation and methodological rigor in basket trials.

Umbrella trials, by contrast, target one type of cancer but divide patients into subgroups according to particular molecular subtypes, giving targeted therapies to the subgroups. The design enables researchers to compare several treatment options in a single tumor type, which will promote precision medicine in a disease-specific environment. Indicatively, among a single cancer like non-small cell lung cancer, the patients can be assigned to various therapeutic arms based on their biomarker status. Umbrella trials therefore offer a feasible platform to also investigate the relative efficacy of various targeted therapies within a unified study setting. Nevertheless, they are not devoid of them: the demand to have molecular diagnostics of high accuracy can be resource-intensive, and subgroups can be small in question, lowering statistical power and making the results interpretation harder. Regardless of these limitations, umbrella trials are an effective and patient-centric methodology, which allows optimizing the choice of therapies and enhancing clinical outcomes in a single cancer population.

Platform trials take the concept of adaptive trial to an even greater extent by using ongoing master protocols, which provide room to keep on changing trial arms in response to interim results. In contrast to traditional, non-perpetual, trials, platform trials are constructed to be continuous, where the non-effective treatments can be removed and new investigational therapies are added without distracting the trial structure. One of the most striking examples is the I-SPY 2 trial of breast cancer, whereby unproductive treatment arms are quickly abandoned and promising treatments are added in real-time, thus saving time and money and accelerating the identification of effective treatments. This very versatile model enables real life learning and adaptive decision-making and is therefore one of the most effective tools to use in the current oncology research. Nevertheless, the logistics of platform trials are large: they require complex statistical modeling, powerful trial management systems, and effective regulatory controls to guarantee validity and interpretability of outcomes. The practical and logistical issues highlight the importance of immense infrastructure, partnership, but when done properly, platform trials are a groundbreaking strategy of speeding up the development of cancer therapy.

ISBN: 978-81-985724-3-1

1. Basket Trials

- **Idea:** Basket trials the concept of basket trials is designed to test one therapeutic agent in a group of tumor types with a common molecular alteration, e.g. a particular genetic mutation. In contrast to classical trials involving the grouping of patients by the tissue that the tumor originates, basket trials are based on the common molecular target to all cancers and investigates whether the drug can generate an effect regardless of the anatomical origin of the tumor. This strategy relies on the concept of precision oncology in which molecular features, instead of histology are used to select therapy.
- **Bonus:** The ultimate aim of basket trials is to determine which tumors are sensitive to a directed treatment irrespective of their tissue of origin. Through this, researchers will be able to decide on whether a molecularly focused agent could be efficient on different types of cancer, indicating wider clinical signs of rare mutations.
- **Example:** A typical example is a drug targeting the BRAF V600E mutation that can be used along with melanoma, colorectal cancer, and non-small cell lung cancer. This design will give the trial the opportunity to assess whether the presence of the mutation is correlated with therapeutic response in these different tumor types, to emphasize the mutation-driven and not tissue-driven treatment model.
- **Benefits:** Basket trials are especially effective when it comes to researching rare mutations that take place in various types of cancers, and in these cases, it is possible to pool patients with diverse cancers. This design saves on time; patient numbers and resources as opposed to the use of independent clinical trials per type of cancer.
- **Challenges:** The tumor microenvironment may impact a drug's efficacy, and these differences may occur in different tissues, resulting in different responses. In addition, statistical interpretation can be complicated because treatment effects can vary depending on the tumor subgroups and thus close subgroup analyses and strict interpretation of results are necessary.

2. Umbrella Trials

- **Concept:** The principle of umbrella trials is meant to test a number of targeted therapies in a single tumor type. Patients are divided into molecular subtypes of the disease; a therapy is given to each subgroup which is expected to be effective on the basis of the molecular profile of their tumor. The method will enable the concurrent testing of multiple therapies and still focus on a single type of cancer.

ISBN: 978-81-985724-3-1

- **Goal:** The overall objective is to pair every patient with a therapy that is likely to be effective against his or her particular molecular subtype, allowing a very specific treatment approach even within an individual disease. Umbrella trials will improve precision oncology across a single cancer type by linking treatment with molecular properties of that cancer type.
- **Examples:** In lung cancer, the EGFR, ALK, KRAS and ROS1 can be stratified with each subgroup undergoing a specific targeted therapy based on their molecular alteration. This allows the trial to be a test of several therapies at the same time under a single umbrella protocol, simplifying the assessment and resource consumption.
- **Benefits:** Umbrella trials allow personalized medicine in one tumor type and allow the efficient utilization of patient cohorts and trial infrastructure, as more than one treatment regimen can be evaluated in parallel instead of in series.
- **Challenges:** The only way to do umbrella trials is to have a very powerful molecular diagnostics in order to categorize the patients properly under the corresponding subgroups. Moreover, certain subgroups might be of small size and this can reduce statistical power and reduce the ability to detect high treatment effects.

3. Platform Trials

- **Concept:** Platform trials are based on master protocols that permit treatment arms to be added or taken away as interim analyses occur. In such adaptive trials, several therapies or combinations are continuously tested in the course of time without the necessity to start a trial with each new intervention.
- **Goal:** The goal is to maximise flexibility and efficiency, such that multiple therapies can be assessed in real time and promising new treatments can be incorporated and unsuccessful ones discontinued fast. Platform trials especially are best adapted to assessing changing treatment opportunities and to expedite therapeutic discovery.
- **Example: I**-SPY 2 trial in breast cancer is a famous platform trial which presents several investigational drugs in parallel. Ineffective treatment arms are not retained long enough and new agents can be initiated without initiating a new protocol, resulting in faster identification of effective therapies.
- **Strengths:** Platform trials save money and time of trial because they use one master protocol. They enable real time learning by continuous data and permit quick

ISBN: 978-81-985724-3-1

incorporation of novel medicines, enhancing proficiency in clinical advancement and permitting adaptive judgment depending on early outcomes.

- **Challenges:** Platform trials require intricate study design, advanced statistical modelling, and legal control. These trials demand sophisticated infrastructure and trial management systems to manage dynamic changes in arms of treatment, interim analysis and adaptive rules, and therefore are operationally more difficult than traditional trials.

9.2. STRATIFYING PATIENTS BASED ON MOLECULAR ALTERATIONS

The key concept of precision oncology is patient stratification according to the molecular features of the specific tumor, and the treatment can be adapted to each individual biological profile. Although tumors might look like each other when viewed under a microscope, they may contain different genetic, transcriptomic, or proteomic differences, which determine how they respond to treatment. Molecular profiling Molecular profiling (i.e. genomic sequencing, RNA expression analysis, proteomics etc.) enables clinicians to determine predictive biomarkers, identifying those patients with the highest likelihood of response to treatment. This strategy guarantees that the treatment is guided, directed to responsive patients and other patients are spared unnecessary treatment which may be ineffective or even harmful and finally lead to better outcomes and avoid toxicity which is not necessary.

In addition to personalized therapy of the patient, molecular stratification is also important in the design of clinical trials. The trials could now be more accurately able to assess the investigational therapy efficacy by grouping patients based on biologically relevant characteristics, in well defined subpopulations. This focused structure will maximize the chances of observing significant therapeutic effects and resource use, and hasten the creation of novel treatment. Moreover, stratification can be used to identify knowledge about tumor biology, drug resistance mechanism, and possible combination approaches, which can ultimately bring the field of oncology closer to personalized and effective care.

➢ Common Stratification Approaches

- **Genomic Alterations:** The DNA level alteration which influences tumor behavior can be used to stratify patients. Drug sensitivity or resistance can depend on somatic mutations in important oncogenes or tumor suppressor genes (including KRAS, BRAF, or TP53). Variations in copy number can help to understand the dose effect of genes that could influence the response to the treatment, and gene fusions such as ALK and

ISBN: 978-81-985724-3-1

NTRK rearrangements tend to become actionable targets that can be targeted with a given inhibitor. These genomics attributes have effectively acted as directing agents in therapy selection and enrolment in clinical trials.

- **Transcriptomic and Proteomic Signatures:** It is also possible to stratify using transcriptomic and Proteomic Signatures which reflect functional tumor behavior at levels beyond those of DNA sequence alone. An example is the expression signature of the PAM50 gene in breast cancer that is used to categorize tumors into intrinsic subtypes that have different prognoses and different sensitivities to therapy. Likewise, protein abundance and activation states, measured by proteomic analysis, such as phosphoproteomics, give information about signaling pathways, which can be used to guide selection of targeted therapies.
- **Epigenetic Markers:** Molecular stratification may also be enriched with epigenetic features, including the patterns of DNA methylation, which have proven to predict the response to some therapies. The markers are used to give further layers of information, which is complementary to the genomic and transcriptomic data, and enable clinicians to target treatment solutions to achieve improved patient-specific outcomes.
- **Immunological Profiles:** In immunotherapy-based therapies, immunotherapy is often stratified based on the following markers: tumor mutational burden (TMB), microsatellite instability (MSI) and the level of PD-L1 expression. Such immunological characteristics aid the detection of patients who are likely to respond to checkpoint inhibitors or other immunomodulators to initiate a targeted distribution of immunotherapy and greater clinical effects.

➢ **Workflow for Stratification**

Molecular stratification uses a workflow of steps to achieve appropriate and practical classification of patients:

1. **Collection of the sample:** Patient samples may be obtained by a standard tissue biopsy or by such a non-invasive approach as a circulating tumor DNA (ctDNA). Liquid biopsies have the benefit of longitudinal monitoring of tumor evolution, identifying new mutations, and characterizing tumor heterogeneity that can arise during therapy, with the benefit of repeated sampling over time.

2. **High-Throughput Profiling:** The samples are high-throughput profiled using molecular profiling methods after they have been obtained. They are next-generation

ISBN: 978-81-985724-3-1

sequencing (NGS) DNA analysis, RNA sequencing (RNA-seq) to understand gene expression pattern, and proteomic studies to assess protein-level changes. Combined, these methods produce extensive molecular data sets, which allow in-depth insights into the biological landscape of the tumor.

3. **Bioinformatics Analysis:** The molecular datasets undergo a high-level set of computation pipelines. Bioinformatics tools are used to identify mutations that can be acted upon, describe the expression characteristics, and identify patient subgroups or clusters which may respond variably to treatment. This analysis transforms raw molecular data into clinically useful information, to support informed decision-making in order to adopt personalized treatment plans.

4. **Treatment Assignment:** The individual patients are matched to a particular treatment arm or targeted therapy through the molecular analysis that most effectively matches with the biological features of the tumor. This will allow customizing the selection of therapy and, to the greatest extent, increase the chances of a clinical effect and reduce the exposure to non-effective treatments in accordance with the principles of precision medicine.

➢ **Challenges**

Although promising, molecular stratification has a number of serious issues:

- **Tumor Evolution and Heterogeneity:** Tumor is not intended to be a fixed set of mutations; it is a dynamic entity that continually changes. It is possible that mutational profiles can change with time, as a consequence of intrinsic tumor evolution, or by the selective forces of therapy. Such alterations can undermine molecular stratification accuracy because a patient can no longer have a tumor that matches the profile that was initially applied in the treatment decisions, which may impact the efficacy and clinical outcome of the treatment.

- **Technical Limitations:** Technical performance of the assays used is very crucial to the efficacy of molecular stratification. The sensitivity of detection methods, sequences coverage, and depths can also be a limitation to identify low-frequency mutations or infrequent molecular events. Such technical limitations can affect appropriate patient referral to specific treatments and the success of precision oncology treatments in general.

ISBN: 978-81-985724-3-1

- **Publications:** The Advanced molecular testing is not universally available, and its application in precision oncology also raises some ethical issues that pertain to fairness, equity, and inclusivity. The differences in access may deny some groups access to personalized treatment strategies. Fair access to molecular diagnostics is one significant challenge to harnessing precision oncology out of the research context and into the general clinical practice.

9.3. REAL-WORLD EVIDENCE AND DATA-DRIVEN TRIAL DESIGN

Real-world evidence (RWE) refers to clinical information gathered in the real-world, beyond the confines of the formalized procedures of randomized clinical trials (RCTs). In contrast to RCT that is meant to test efficacy and safety in highly controlled settings, RWE reflects the experience of patients in regular medical care, including those with comorbidities, different levels of adherence, or different demographic/socioeconomic characteristics. This renders RWE especially useful in the context of information about treatment performance across larger, more general heterogeneous populations, which counteracts the generalizability shortcomings that tend to be present in traditional clinical trials. RWE offers a reflection on the complexity of care in the real-life setting, giving insights into the treatment effectiveness, safety, and patient outcomes in situations that cannot be adequately reproduced in the RCT.



Figure 2: Sources of Real-World Data (RWD)

Source: (https://toolbox.eupati.eu/resources/patient-toolbox/real-world-data-rwd-real-world-evidence-rwe/)

ISBN: 978-81-985724-3-1

RWE is obtained in various sources, such as electronic health records, insurance claims, patient registries, mobile health applications, and even wearable devices. These data enable the researcher and clinician to measure long-term outcomes, observe rare adverse events, and also measure the interventions in various healthcare contexts. Combined with RCT-based evidence, RWE can reinforce clinical judgment by providing additional supportive evidence to guide guideline development, policy-making, and personal patient care. Moreover, regulatory authorities are progressively appreciating the importance of RWE in not only justifying drug approvals, post-marketing surveillance, and health technology evaluations, but also playing an ever-increasing role in filling the gap between the controlled trial data and actual clinical practice.

Sources of RWE include:

- **Electronic Health Records (EHRs):** EHRs are a rich source of both structured and unstructured clinical information, such as diagnostic notes, imaging reports, prescriptions, laboratory results and longitudinal treatment histories. These datasets provide detailed information on the efficacy of therapies in the non-trial environments.
- **Registries and observational cohorts:** Disease-based registries and observational cohort studies follow patient outcomes in the long term. These sources are useful to learn the long term trends in the survival, trends in resistance to treatment, and differences in practice within institutions.
- **Claims/billing data:** Insurance claims are used to record the healthcare usage, treatment expenses, and hospital admissions. They are not clinically described in greater detail but are critical to large-scale epidemiological evaluation, economic evaluation, and health outcomes research.
- **Wearables and patient-report outcomes (PROS):** Digital healthcare tools including wearable devices, mobile applications and self-report platforms provide real-time and continuous data on lifestyle, quality of life, symptom burden and treatment side effects. Such contributions give a patient-focused view that is usually absent in standard clinical trials.

Uses in Trial Design

- **The use of Real-World Evidence (RWE) in Clinical Trials:** Evidence Real-world evidence is now a cornerstone in contemporary clinical trial designs, supplementing the

ISBN: 978-81-985724-3-1

previous conventional randomized controlled trials (RCTs) and broadening the evidence-generating potential. RWE enhances hypothesis generation, trial performance, and post-approval observations through the use of data available electronically, via health records (EHRs), registries, claims databases, and other real-world data.

- **Hypothesis generation:** With RWE, researchers are able to search enormous, heterogeneous data in order to discover new patterns and derive new hypotheses to study clinical research. Indicatively, the retrospective EHR analyses might point to the fact that patients with a particular genetic mutation or demographic profile or a comorbidity do not react to a particular therapy. These observations are priceless in designing the targeted and precision-focused clinical trials that are more closely consistent with real-world treatment responses.
- **Patient selection and enrichment:** Trial populations can be selected and stratified on the basis of RWE to enrich and select individuals with the highest probability of responding to investigational therapies. An example is that biomarker-positive patients that may have a favorable response to a treatment can be identified in the registries and genomic databases, which can increase the efficiency of the trial, increase the statistical power and shorten the total sample size needs.
- **Historical controls:** In an environment like rare cancers or small groups of patients, it is not always feasible to recruit large and balanced control groups. RWE is a useful alternative as it will provide external control groups based on the historical patient outcome data. This method eliminates the participant overload, eliminates any ethical issue of withholding treatment, and is scientifically valid in the case of limited randomization.
- **Post-marketing surveillance:** After approval, RWE is important in the real-world application of the therapies during the long-term. It promotes the identification of uncommon or untimely adversarial incidents, measures ongoing effectiveness, and evaluates safety in larger and more heterogeneous groups of patients who might not have been reflected in pivotal research. This continuous generation of evidence facilitates regulatory decision-making and is informative of clinical practice guidelines.

ISBN: 978-81-985724-3-1

Adaptive, Data-Driven Design

The real-world evidence (RWE) is progressively integrated into the modern clinical trial design together with adaptive methodology, providing flexible, responsive designs that are updated in accordance with the accruing data. The above paradigm shift increases the efficiency of trials, boosts ethics by ensuring fewer patients are exposed to ineffective therapies and boosts external validity by ensuring results are more representative of clinical practice in the real world. The essence of this strategy is.

- **Interim analyses:** Dynamic changes can be made without affecting scientific validity and regulatory compliance by pre-specified analysis at designated times in a trial. These analyses are necessary in making informed decisions and can include various forms of adjustments, which include:
    - **Dropping ineffective treatment arms:** Removing arms that exhibit low-efficacy to preserve patients against unreasonable risk and rationalize the resources of trials.
    - **Growing enrollment in promising subgroups:** Recruiting more patients into select groups that already indicate high response rates, thus hastening the production of evidence in select groups.
    - **Secondary Endpoint Adjustments:** Adjusting dose, schedule or primary/secondary endpoint in response to emerging clinical information in order to maximize therapeutic effects and match patient requirements.
- **Statistical and computational approaches:** The combination of developed statistical models and computing software has changed adaptive trial design into more powerful and predictive.
    - **Bayesian statistics:** Offer a very versatile model of continuous evidence updating, in which prior information is combined with data obtained recently. The methodology permits updating of decisions in real time during trial, not until full data lock, and keeps error rates under control.
    - **Machine learning models:** Machine learning methods can predict patient outcomes, optimize the utilization of participants in trial arms, and make adaptive changes in real-time, because they can handle high-dimensional and heterogeneous data-types, including imaging, genomic profiles, and electronic health records. These models increase the accuracy of clinical trials and allow conducting a more individual approach to the assessment of therapies.

ISBN: 978-81-985724-3-1

➢ **Advantages of RWE-Driven Designs**

- **Quicker drug assessment:** Placing clinical trials in a standard healthcare environment and utilizing the existing real-world data can help make drug assessment much quicker. This is because the method can lead to results much faster than conventional randomized controlled trials (RCTs), and thus promising therapies can reach patients within a shorter period and still be scientifically rigorous.

- **Less patient exposure to ineffective treatments:** Adaptive trial designs enable an early identification and discontinuation of trial arms that are not demonstrating therapeutic value. It decreases patient exposure to non-effective or potentially detrimental treatment and improves patient safety and makes sure that resources are directed towards interventions with the best chance of success.

- **Combination of heterogeneous data:** Trials that use real-world evidence (RWE) combine various data streams, such as electronic health records (EHRs), molecular and genomic data, imaging findings, and patient-reported outcomes. This holistic method offers a more holistic, patient-centered view of treatment performance in various patient groups that allow subtle information on effectiveness, safety, and treatment response variability.

- **Improved generalizability:** Since RWE is developed by using the diversity in the real-world patient populations such as older adults, patients with multiple comorbidities, and generally underrepresented in traditional RCTs, the results of RWE-based trials are more generally applicable. This increases external validity of the findings and makes the conclusions applicable to the entire range of patients who ultimately will be subjects of the therapy.

9.4. REGULATORY CHALLENGES AND EVOLVING GUIDELINES

Basket, umbrella, and platform trials (adaptive and innovative trial designs) are novel concepts that provide more flexibility than ever before in oncology research and permit changes in treatment arms, dosages, and endpoints in response to interim results. Although these designs enhance efficiency and patient-centricity, they come with immense challenges, such as statistical complexity, operational issues, and ethical issues. Close supervision is necessary to maintain adequate control groups, to guarantee fairness in the allocation of patients and to address dynamic changes without undermining the validity of the trials. Moreover, the

ISBN: 978-81-985724-3-1

algorithmic combination of various datasets, such as genomics, imaging, electronic health records, and real-world evidence poses the risk of standardization, reproducibility, and data quality that is critical to the attainment of credible results and regulatory compliance. The classic regulatory opportunities, which assume the use of fixed two-arm randomized trials, may not be able to fit such adaptive structures, requiring updated approval mechanisms and close attention to ethics.

The FDA and EMA regulatory agencies have acted with changing guidance to enable adaptive and real-world evidence-based trials. FDA promotes pre-specified adaptation regulations, Bayesian statistics to interpret an interim examination, and incorporation of real-world data, especially when rare cancer or post-marketing research is required. On the same note, the EMA encourages patient selection based on biomarkers, heterogeneous population master protocols and the adoption of surrogate endpoints in the absence of overall survival data. Regulatory compliance best practices focus on pre-specification of rules of adaptation, statistical rigor, transparent documentation and high-quality standards in all data sources. Interaction with regulators early is essential to align the objectives of the trials with approval expectations to lessen the uncertainty and increase the chance that adaptive trials can deliver credible actionable findings and protect patient safety and ethical considerations.

- **Key Challenges**
  - **Complexity of trial design:** Adaptive, basket, umbrella, and platform trials allow dynamic changes—such as adding or removing treatment arms, adjusting dosages, or redefining endpoints—based on interim results. While these designs increase efficiency, they introduce statistical and operational complexities. Regulatory bodies must ensure that frequent modifications do not compromise trial validity or introduce hidden biases. Establishing proper control groups and ensuring comparability across changing trial arms is particularly difficult.
  - **Data quality and reproducibility:** Integration of diverse datasets—including multi-center imaging, genomics, electronic health records, and real-world evidence (RWE)—poses challenges for standardization, reproducibility, and data harmonization. Regulators require data to be traceable, consistent, and validated. Incomplete or poorly curated datasets may undermine the reliability of results, making regulatory approval difficult.

ISBN: 978-81-985724-3-1

- **Approval pathways:** Traditional regulatory frameworks, developed for classical two-arm randomized controlled trials, do not always align with adaptive trial structures. Agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have historically relied on fixed designs with predefined endpoints. Adaptive designs—by contrast—require continuous evaluation and updated decision-making, necessitating revised approval pathways and more flexible regulatory approaches.
- **Ethical oversight:** Dynamic allocation of patients to trial arms, dropping of ineffective treatments, or introduction of new therapies during the trial can create ethical concerns. Institutional Review Boards (IRBs) must ensure that patients are fully informed about potential changes and that informed consent documents are updated accordingly. Maintaining fairness in patient allocation while balancing scientific efficiency with patient protection is an ongoing challenge.

➢ **Evolving Guidelines**

FDA guidance (2019, 2020): In recent years, the FDA has issued more updated guidance documents to help meet the increasing complexities of adaptive trial approaches and the introduction of real-world evidence (RWE) into the regulatory process. These updates underscore how the agency strives to create innovation without sacrificing the scientific rigor and patient safety. The key points include:

- **Underpinning the adaptive trial designs:** The FDA acknowledges the value of flexibility in clinical trials and promotes adaptive designs where easily pre-specified adaptation rules are involved. These rules offer transparency, reduce bias and make sure that changes in the parameters of the trials, including sample size, treatment arms or endpoints, are guided by objective criteria instead of subjective decision-making.
- **The utilization of RWE:** To supplement the traditional randomized controlled trials (RCTs), the FDA has focused on the utilization of real-world evidence in regulatory submissions, especially in the spheres where RCTs are not possible to conduct. This is particularly applicable to rare cancers where a small number of patients will not allow the conduct of large-scale trials and post-marketing trials to monitor long-term safety and effectiveness.
- **Permitting Bayesian statistical approaches:** Bayesian statistical approaches in interim analyses are also promoted by the FDA guidance. The techniques aid in ongoing learning because they update probabilities when new information is received.

ISBN: 978-81-985724-3-1

Simultaneously, they assist in the correct regulation of the number of errors, and thus better-informed decisions concerning the development of the trial, its amendments, or early termination in case of need.

EMA guidelines: The European Medicines Agency (EMA) has presented guidelines in support of more adaptive and dynamic regulatory frameworks, especially where the field of oncology research is in a complex and fast changing scenario. The recommendations are intended to strike a balance between scientific rigor and the necessity to be efficient in meeting urgent medical demands, in particular in rare cancers and heterogeneous patient groups. The key points include:

- **Master protocols:** The EMA encourages use of master protocol trial designs e.g. basket trials, umbrella trials, and platform trials to facilitate drug development. These techniques enable the study of several therapies or disease subtypes at the same time within one and broad umbrella and result in less and more efficient redundancy, time, and efficiencies in the analysis of therapies against rare cancers and diverse populations.
- **The focus on biomarker-driven patient selection:** The EMA lays a lot of emphasis on the use of biomarkers to direct patient selection taking into consideration the importance of precision medicine. Biomarker-based trials increase the likelihood of proving efficacy, minimize trials efficiency, and decrease non-responders' needless exposure to trial therapies by enriching the trials with individuals most likely to respond to a specific therapy.
- **Acceptance of surrogate endpoints and real-world outcomes:** To ideate access to potentially life-saving therapies, the EMA permits the use of surrogate endpoints, e.g., progression-free survival or objective response rates, to be used as appropriate measures in cases where overall survival data are not yet mature. Besides that, the agency recognizes the emerging significance of real-world outcomes, which are important to gain profound understanding of the effectiveness of treatment, quality of life among patients and their long-term safety in clinical practice settings.

➢ **Best Practices for Regulatory Compliance**

Researchers have an opportunity to adhere to the best practices to successfully navigate regulatory processes in adaptive and RWE-driven trials:

- **Pre-specify adaptation rules:** It is necessary to state clearly in the trial protocol the particular rules and criteria that may be used in any case of adaptation. This involves

ISBN: 978-81-985724-3-1

ISBN: 978-81-985724-3-1

the description of situations when trial arms can be dropped, added or changed. These rules can be set beforehand, thereby reducing the possibility of bias and making decisions transparent in a trial that preserves the integrity of study results.

- **Ensure statistical rigor:** Statistical rigor is important in adaptive trials, especially due to the fact that repeated adaptations may promote type I errors (false positives). With proper planning and application of the relevant statistical techniques, the validity of the findings can be maintained so that the results can be interpreted and reliable even when interim changes are made or complex trial designs are used.
- **Clear documentation:** This is essential in the adaptive trial process as it is well documented and transparent. These involve recording of the interim results, decision making procedure and reasons as to why there might be any modification made during the trial. Detailed documentation does not only justify regulatory review, but also exhibits accountability to institutional review boards (IRBs) and other control agencies.
- **Quality control:** High-quality data is the basis of all conclusions of trials. Strict validation processes are to be implemented in molecular assays, biomarkers, imaging modalities, and real-world evidence (RWE) sources. Making sure that data is accurate, reproducible, and reliable will help in enhancing the level of credibility of study findings and minimizing the chances of false interpretations.
- **Early cooperations with regulating agencies:** It is important to discuss with regulatory agencies, including FDA, EMA, and other agencies, the trial design process early. The benefits of early collaboration include harmonizing trial objectives and design with regulatory expectations, less uncertainty about what is needed to get the fictitious trial approved, and a higher likelihood that the results of the trial will be of regulatory acceptance standard.

ISBN: 978-81-985724-3-1

REFERENCES

1. Brown, L. C., Graham, J., Fisher, D., Adams, R., Seligmann, J., Seymour, M., ... & FOCUS4 Trial Investigators. (2022). Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. *Clinical Trials*, *19*(2), 146-157.
2. Robertson, D. S., Lee, K. M., López-Kolkovska, B. C., & Villar, S. S. (2023). Response-adaptive randomization in clinical trials: from myths to practical considerations. *Statistical science: a review journal of the Institute of Mathematical Statistics*, *38*(2), 185.
3. Nimmagadda, V. S. P. (2024). Using AI to Improve Success Rates of Clinical Trials Through Advanced Patient Stratification Techniques. *American Journal of Data Science and Artificial Intelligence Innovations*, *4*, 342-379.
4. Ghadessi, M., Tang, R., Zhou, J., Liu, R., Wang, C., Toyoizumi, K., ... & Beckman, R. A. (2020). A roadmap to using historical controls in clinical trials–by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG). *Orphanet journal of rare diseases*, *15*(1), 69.
5. Feng, M., Suresh, K., Schipper, M. J., Bazzi, L., Ben-Josef, E., Matuszak, M. M., ... & Lawrence, T. S. (2018). Individualized adaptive stereotactic body radiotherapy for liver tumors in patients at high risk for liver damage: a phase 2 clinical trial. *JAMA oncology*, *4*(1), 40-47.
6. Garralda, E., Dienstmann, R., Piris-Giménez, A., Braña, I., Rodon, J., & Tabernero, J. (2019). New clinical trial designs in the era of precision medicine. *Molecular oncology*, *13*(3), 549-557.
7. Winter, S., Shoaie, S., Kordasti, S., & Platzbecker, U. (2020). Integrating the "immunome" in the stratification of myelodysplastic syndromes and future clinical trial design. *Journal of Clinical Oncology*, *38*(15), 1723-1735.
8. Fountzilas, E., Tsimberidou, A. M., Vo, H. H., & Kurzrock, R. (2022). Clinical trial design in the era of precision medicine. *Genome medicine*, *14*(1), 101.
9. Gajjar, A., Robinson, G. W., Smith, K. S., Lin, T., Merchant, T. E., Chintagumpala, M., ... & Northcott, P. A. (2021). Outcomes by clinical and molecular features in children with medulloblastoma treated with risk-adapted therapy: results of an international phase III trial (SJMB03). *Journal of Clinical Oncology*, *39*(7), 822-835.

10. Kalinin, A. A., Higgins, G. A., Reamaroon, N., Soroushmehr, S., Allyn-Feuer, A., Dinov, I. D., ... & Athey, B. D. (2018). Deep learning in pharmacogenomics: from gene regulation to patient stratification. *Pharmacogenomics*, *19*(7), 629-650.
11. Spiegelberg, L., Houben, R., Niemans, R., de Ruysscher, D., Yaromina, A., Theys, J., ... & Dubois, L. J. (2019). Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials. *Clinical and translational radiation oncology*, *15*, 62-69.
12. Kiernan, M. C., Vucic, S., Talbot, K., McDermott, C. J., Hardiman, O., Shefner, J. M., ... & Turner, M. R. (2021). Improving clinical trial outcomes in amyotrophic lateral sclerosis. *Nature Reviews Neurology*, *17*(2), 104-118.
13. Hu, C., & Dignam, J. J. (2019). Biomarker-driven oncology clinical trials: key design elements, types, features, and practical considerations. *JCO Precision Oncology*, *1*, 1-12.
14. Gonsalves, W. I., Buadi, F. K., Ailawadhi, S., Bergsagel, P. L., Chanan Khan, A. A., Dingli, D., ... & Roy, V. (2019). Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. *Bone marrow transplantation*, *54*(3), 353-367.
15. Rello, J., Van Engelen, T. S. R., Alp, E., Calandra, T., Cattoir, V., Kern, W. V., ... & Wiersinga, W. J. (2018). Towards precision medicine in sepsis: a position paper from the European Society of Clinical Microbiology and Infectious Diseases. *Clinical Microbiology and Infection*, *24*(12), 1264-1272.

ISBN: 978-81-985724-3-1